EMEA-002597-PIP07-21
Key facts
| Active substance |
Efgartigimod alfa
|
| Therapeutic area |
Dermatology
|
| Decision number |
P/0538/2021
|
| PIP number |
EMEA-002597-PIP07-21
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of pemphigus
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Argenx
Email: regulatory@argenx.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|